Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
AverageWe are a leading global manufacturer in the design and production of technologically advanced, high-quality, integrated containment and delivery systems for injectable drugs and healthcare products. Our products include a variety of primary proprietary packaging, containment solutions, reconstitution and transfer systems, and drug delivery systems, as well as contract manufacturing, analytical lab services and integrated solutions.
In the company’s own words · 10-K filed Feb 17, 2026 · SEC EDGAR
Business segments
Jun 2026 · $872.3MThe company’s own SEC segment disclosure.
- Proprietary Products$722.6M83%
- West Vantage$149.7M17%
West Pharmaceutical Services (WST) reported revenue of $845M in Q1 2026 (quarter ended Mar 31, 2026), up 21% from the same quarter a year earlier. That came with a gross margin of 35% and net income of $139M (16% of revenue). For the full year FY2025, revenue was $3.07B (+6.3% year on year) and net income $494M. Its largest segment in Jun 2026 was Proprietary Products at $723M, 83% of the disclosed total, well ahead of West Vantage at 17%.
Raw charts
11 series · TTMAs reported to the SEC, without any scoring.
Medical Instruments & Supplies
The closest names by size in the same industry